Low adenovirus vaccine doses administered to skin using microneedle patches induce better functional antibody immunogenicity as compared to systemic injection

Adenovirus-based vaccines are demonstrating promising clinical potential for multiple infectious diseases, including COVID-19. However, the immunogenicity of the vector itself decreases its effectiveness as a boosting vaccine due to the induction of strong anti-vector neutralizing immunity. Here we...

Full description

Bibliographic Details
Main Authors: Flynn, O, Dillane, K, Lanza, JS, Marshall, JM, Jin, J, Silk, SE, Draper, SJ, Moore, AC
Format: Journal article
Language:English
Published: MDPI 2021
_version_ 1826310194183798784
author Flynn, O
Dillane, K
Lanza, JS
Marshall, JM
Jin, J
Silk, SE
Draper, SJ
Moore, AC
author_facet Flynn, O
Dillane, K
Lanza, JS
Marshall, JM
Jin, J
Silk, SE
Draper, SJ
Moore, AC
author_sort Flynn, O
collection OXFORD
description Adenovirus-based vaccines are demonstrating promising clinical potential for multiple infectious diseases, including COVID-19. However, the immunogenicity of the vector itself decreases its effectiveness as a boosting vaccine due to the induction of strong anti-vector neutralizing immunity. Here we determined how dissolvable microneedle patches (DMN) for skin immunization can overcome this issue, using a clinically-relevant adenovirus-based Plasmodium falciparum malaria vaccine, AdHu5–PfRH5, in mice. Incorporation of vaccine into patches significantly enhanced its thermostability compared to the liquid form. Conventional high dose repeated immunization by the intramuscular (IM) route induced low antigen-specific IgG titres and high anti-vector immunity. A low priming dose of vaccine, by the IM route, but more so using DMN patches, induced the most efficacious immune responses, assessed by parasite growth inhibitory activity (GIA) assays. Administration of low dose AdHu5–PfRH5 using patches to the skin, boosted by high dose IM, induced the highest antigen-specific serum IgG response after boosting, the greatest skewing of the antibody response towards the antigen and away from the vector, and the highest efficacy. This study therefore demonstrates that repeated use of the same adenovirus vaccine can be highly immunogenic towards the transgene if a low dose is used to prime the response. It also provides a method of stabilizing adenovirus vaccine, in easy-to-administer dissolvable microneedle patches, permitting storage and distribution out of cold chain.
first_indexed 2024-03-07T07:48:30Z
format Journal article
id oxford-uuid:700b63bc-c0ef-4494-b221-2001594e5c59
institution University of Oxford
language English
last_indexed 2024-03-07T07:48:30Z
publishDate 2021
publisher MDPI
record_format dspace
spelling oxford-uuid:700b63bc-c0ef-4494-b221-2001594e5c592023-06-29T13:18:00ZLow adenovirus vaccine doses administered to skin using microneedle patches induce better functional antibody immunogenicity as compared to systemic injectionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:700b63bc-c0ef-4494-b221-2001594e5c59EnglishSymplectic ElementsMDPI2021Flynn, ODillane, KLanza, JSMarshall, JMJin, JSilk, SEDraper, SJMoore, ACAdenovirus-based vaccines are demonstrating promising clinical potential for multiple infectious diseases, including COVID-19. However, the immunogenicity of the vector itself decreases its effectiveness as a boosting vaccine due to the induction of strong anti-vector neutralizing immunity. Here we determined how dissolvable microneedle patches (DMN) for skin immunization can overcome this issue, using a clinically-relevant adenovirus-based Plasmodium falciparum malaria vaccine, AdHu5–PfRH5, in mice. Incorporation of vaccine into patches significantly enhanced its thermostability compared to the liquid form. Conventional high dose repeated immunization by the intramuscular (IM) route induced low antigen-specific IgG titres and high anti-vector immunity. A low priming dose of vaccine, by the IM route, but more so using DMN patches, induced the most efficacious immune responses, assessed by parasite growth inhibitory activity (GIA) assays. Administration of low dose AdHu5–PfRH5 using patches to the skin, boosted by high dose IM, induced the highest antigen-specific serum IgG response after boosting, the greatest skewing of the antibody response towards the antigen and away from the vector, and the highest efficacy. This study therefore demonstrates that repeated use of the same adenovirus vaccine can be highly immunogenic towards the transgene if a low dose is used to prime the response. It also provides a method of stabilizing adenovirus vaccine, in easy-to-administer dissolvable microneedle patches, permitting storage and distribution out of cold chain.
spellingShingle Flynn, O
Dillane, K
Lanza, JS
Marshall, JM
Jin, J
Silk, SE
Draper, SJ
Moore, AC
Low adenovirus vaccine doses administered to skin using microneedle patches induce better functional antibody immunogenicity as compared to systemic injection
title Low adenovirus vaccine doses administered to skin using microneedle patches induce better functional antibody immunogenicity as compared to systemic injection
title_full Low adenovirus vaccine doses administered to skin using microneedle patches induce better functional antibody immunogenicity as compared to systemic injection
title_fullStr Low adenovirus vaccine doses administered to skin using microneedle patches induce better functional antibody immunogenicity as compared to systemic injection
title_full_unstemmed Low adenovirus vaccine doses administered to skin using microneedle patches induce better functional antibody immunogenicity as compared to systemic injection
title_short Low adenovirus vaccine doses administered to skin using microneedle patches induce better functional antibody immunogenicity as compared to systemic injection
title_sort low adenovirus vaccine doses administered to skin using microneedle patches induce better functional antibody immunogenicity as compared to systemic injection
work_keys_str_mv AT flynno lowadenovirusvaccinedosesadministeredtoskinusingmicroneedlepatchesinducebetterfunctionalantibodyimmunogenicityascomparedtosystemicinjection
AT dillanek lowadenovirusvaccinedosesadministeredtoskinusingmicroneedlepatchesinducebetterfunctionalantibodyimmunogenicityascomparedtosystemicinjection
AT lanzajs lowadenovirusvaccinedosesadministeredtoskinusingmicroneedlepatchesinducebetterfunctionalantibodyimmunogenicityascomparedtosystemicinjection
AT marshalljm lowadenovirusvaccinedosesadministeredtoskinusingmicroneedlepatchesinducebetterfunctionalantibodyimmunogenicityascomparedtosystemicinjection
AT jinj lowadenovirusvaccinedosesadministeredtoskinusingmicroneedlepatchesinducebetterfunctionalantibodyimmunogenicityascomparedtosystemicinjection
AT silkse lowadenovirusvaccinedosesadministeredtoskinusingmicroneedlepatchesinducebetterfunctionalantibodyimmunogenicityascomparedtosystemicinjection
AT drapersj lowadenovirusvaccinedosesadministeredtoskinusingmicroneedlepatchesinducebetterfunctionalantibodyimmunogenicityascomparedtosystemicinjection
AT mooreac lowadenovirusvaccinedosesadministeredtoskinusingmicroneedlepatchesinducebetterfunctionalantibodyimmunogenicityascomparedtosystemicinjection